Ascendis Pharma A/S (NASDAQ:ASND) Receives “Outperform” Rating from Wedbush

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a research note issued on Tuesday, Benzinga reports. They presently have a $327.00 price objective on the biotechnology company’s stock. Wedbush’s price target suggests a potential upside of 24.32% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. HC Wainwright started coverage on shares of Ascendis Pharma A/S in a research report on Thursday. They set a “buy” rating and a $345.00 price objective for the company. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Bank of America cut their price target on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a report on Monday. Evercore restated an “outperform” rating and issued a $329.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Finally, UBS Group set a $345.00 price objective on Ascendis Pharma A/S in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Ascendis Pharma A/S has an average rating of “Buy” and a consensus target price of $307.65.

Ascendis Pharma A/S Trading Up 6.1%

Shares of ASND stock opened at $263.04 on Tuesday. The company has a market capitalization of $16.41 billion, a P/E ratio of 20.41 and a beta of 0.39. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average is $256.44 and its two-hundred day moving average is $239.47. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The company had revenue of $387.22 million for the quarter, compared to analysts’ expectations of $376.75 million. Equities analysts forecast that Ascendis Pharma A/S will post 3.9 EPS for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 2,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the purchase, the director directly owned 2,900 shares in the company, valued at approximately $714,357. This trade represents a 222.22% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 40.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently made changes to their positions in ASND. Advisory Services Network LLC purchased a new stake in Ascendis Pharma A/S in the 3rd quarter valued at about $26,000. Arax Advisory Partners lifted its holdings in shares of Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG purchased a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at about $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter worth about $42,000. Finally, Global Retirement Partners LLC raised its position in shares of Ascendis Pharma A/S by 111.9% in the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares in the last quarter.

More Ascendis Pharma A/S News

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Settlement and licensing agreement: Ascendis and BioMarin agreed to terms covering the sale of YUVIWEL and related navepegritide products. Investors appear to view the resolution of the disputes as a significant positive catalyst. Ascendis and BioMarin Enter Binding Term Sheet
• Positive Sentiment: Market reaction: Reports indicated that Ascendis shares rose about 6% following the BioMarin license and settlement announcement, highlighting the deal’s near-term importance to investors. Ascendis Pharma Shares Rise Over License Deal
• Neutral Sentiment: Analyst sentiment remains favorable: HC Wainwright maintained a Buy rating and a $345 price target, while the broader analyst average rating was also reported as Buy. Ascendis Pharma Receives Average Buy Rating
• Negative Sentiment: HC Wainwright cut estimates: The firm reduced its EPS forecasts for every listed period, including FY2027 to $11.25 from $11.88 and Q3 2026 to $1.09 from $1.16. The revisions suggest more cautious expectations for Ascendis’ earnings trajectory, although the Buy rating was retained.
• Negative Sentiment: Bank of America trimmed its target: BofA lowered its price objective to $304 from $306 but kept a Buy rating, creating a modestly negative signal alongside the earnings-estimate reductions. Bank of America Lowers Ascendis Price Target

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.